LIVIVO - Search results -

Search results

Result 1 - 10 of total 65

Search options

Article: Management strategies for antidepressant-related sexual dysfunction.

Lach, Frank / Bottemanne, Hugo / Hingray, Coraline / Papeta, Didier / Rousseau, Amélie / Javelot, Hervé

2024

Abstract: Antidepressant-related sexual dysfunction is one of the most frequently met adverse effects for individuals suffering from major depressive disorder. When primary prevention by non-pharmacological measures fails, empirical coping strategies might be ... ...

Abstract	Antidepressant-related sexual dysfunction is one of the most frequently met adverse effects for individuals suffering from major depressive disorder. When primary prevention by non-pharmacological measures fails, empirical coping strategies might be proposed. In this article, we present a brief overview of pharmacological strategies for antidepressant-related sexual dysfunction, considering antidepressants and conceivable corrective medications. We suggest dividing these strategies into three groups: (1) tapering (dose reduction, therapeutic window or short-term treatment interruption); (2) maintenance (focusing on spontaneous remission); (3) optimizing treatment (substitution for another antidepressant or addition of treatments to correct sexual side effects). Whichever strategy is selected, we encourage the clinician to propose the most adequate therapeutic option for the patient, while considering the efficacy and overall tolerance of the current antidepressant strategy, the affected phase of sexuality and patient preferences and gender. This summary is limited to antidepressant treatments and correctors marketed in France and aimed at a clinician reading to help manage patients suffering from antidepressant-induced sexual dysfunction.
Language	English
Publishing date	2024-02-03
Publishing country	France
Document type	Journal Article
ZDB-ID	214431-1
ISSN	0013-7006
ISSN	0013-7006
DOI	10.1016/j.encep.2023.11.025
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ui II Zs.65: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Withdrawal syndrome after antipsychotics discontinuation: an analysis of the WHO database of spontaneous reports (Vigibase) between 2000 and 2022.

Storck, Wilhelm / de Laportalière, Tanguy Taillefer / Yrondi, Antoine / Javelot, Hervé / Berna, Fabrice / Montastruc, François

Psychopharmacology

2024

Abstract: Rationale: Withdrawal syndrome (WDS) has been described after discontinuation of antipsychotics. WDS could be the consequence of an over-activation of the dopaminergic pathway. Antipsychotics with a higher affinity for dopamine D2 receptors could be ... ...

Abstract	Rationale: Withdrawal syndrome (WDS) has been described after discontinuation of antipsychotics. WDS could be the consequence of an over-activation of the dopaminergic pathway. Antipsychotics with a higher affinity for dopamine D2 receptors could be associated with a higher risk of WDS. This study aims to address this statement and evaluate the risk difference for withdrawal syndrome between antipsychotics based on pharmacovigilance data. Methods: We collected individual reports registered in Vigibase® between 01/01/2000 and 31/12/2022 of patients treated with antipsychotics and who had presented WDS. A disproportionality analysis was performed to evaluate the risk of reporting WDS with each antipsychotic compared to all other antipsychotics. We performed a correlation analysis to assess the correlation between the risk of reporting WDS for each antipsychotic in relation with their pKi for D2 and 5HT2A receptors. Results: The most frequent psychiatric withdrawal symptoms after antipsychotic discontinuation were insomnia, anxiety and depression. Tremor, headache and dizziness were among the most frequently reported neurologic withdrawal symptoms. Tiotixene had the highest risk of reporting WDS (ROR 7.08; 95%CI 3.49 - 14.35) followed by pimozide (ROR 4.35; 95%CI 1.93 - 9.77), quetiapine (ROR 4.24; 95%CI 3.87 - 4.64), thioridazine (ROR 4.17; 95%CI 2.50-6.98) and ziprasidone (ROR 2.98; 95%CI 2.41-3.67). We found a poor correlation between D2/5HT2A binding affinity and the risk of reporting withdrawal syndrome (R Conclusion: Our results suggest that there might be a risk difference for WDS between antipsychotics. Tiotixene, pimozide and quetiapine were associated with a higher risk of reporting a WDS whereas this risk was lower with chlorpromazine, clozapine and fluphenazine. We could not address the issue of withdrawal psychosis, withdrawal dyskinesia, rebound psychosis or supersensitivity psychosis due to the lack of specific WHO medDRA coded terms to identify potential cases.
Language	English
Publishing date	2024-02-20
Publishing country	Germany
Document type	Journal Article
ZDB-ID	130601-7
ISSN	1432-2072 ; 0033-3158
ISSN (online)	1432-2072
ISSN	0033-3158
DOI	10.1007/s00213-024-06554-4
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ui I Zs.240: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Association pimavansérine et trazodone dans les troubles du comportementde la maladie à corps de Lewy sévère.

Muller, Candice / Merignac, Jeanne / Moog, Christophe / Schorr, Benoit / Javelot, Hervé / Blanc, Frédéric

Geriatrie et psychologie neuropsychiatrie du vieillissement

2023 Volume 21, Issue 1, Page(s) 116–127

Abstract: Introduction: Dementia with Lewy bodies (DLB) is characterized by neurocognitive disorders associated with core clinical features including hallucinations. There is currently no cure but a combination of symptomatic treatments: clozapine is commonly ... ...

Title translation	Pimavanserin and trazodone combination in behavioral disorders in severe dementia with Lewy bodies.
Abstract	Introduction: Dementia with Lewy bodies (DLB) is characterized by neurocognitive disorders associated with core clinical features including hallucinations. There is currently no cure but a combination of symptomatic treatments: clozapine is commonly used in DLB-related psychosis. Pimavanserin is a serotonin 5HT-2A receptor inverse agonist that has recently been shown to reduce psychosis related to dementia. Trazodone is a serotonin reuptake inhibitor and a 5-HT2 receptor antagonist: it is effective in the treatment of the frontal syndrome and is commonly used in frontotemporal degeneration. Patients and methods: We describe three patients with DLB, hospitalized in the cognitive-behavioral unit of the University Hospitals of Strasbourg, who presented with major visual hallucinations, delusion, and an orbitofrontal syndrome including disinhibition, agitation, and irritability. The 3 patients were intolerant of low-dose Clozapine (neutropenia for one, somnolence for the other and Pisa syndrome and falls for the last one). We evaluated the Neuropsychiatric Inventory (NPI) before and after the introduction of both treatments. Results: Given their psychotic and frontal symptoms, we used Pimavanserin and Trazodone simultaneously. After 4 to 6 weeks of treatment, a marked improvement was observed in all 3 patients, with a decrease of the NPI scores from a mean of 88 to 38. Discussion and conclusion: To our knowledge, there is no previously described combination of these two treatments in DLB. A clinical trial combining these two molecules against pervasive behavioral disorders in DLB would be interesting in view of these preliminary results.
MeSH term(s)	Humans ; Lewy Body Disease/drug therapy ; Lewy Body Disease/diagnosis ; Trazodone/therapeutic use ; Clozapine/therapeutic use ; Drug Inverse Agonism ; Dementia/psychology ; Hallucinations/drug therapy
Chemical Substances	Trazodone (YBK48BXK30) ; pimavanserin (JZ963P0DIK) ; Clozapine (J60AR2IKIC)
Language	French
Publishing date	2023-05-01
Publishing country	France
Document type	English Abstract ; Journal Article
ISSN	2115-7863
ISSN (online)	2115-7863
DOI	10.1684/pnv.2023.1092
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- Full text online
- Order with fees

Article ; Online: Benefit of long-acting paliperidone in Huntington's disease: a case report.

Javelot, Hervé / Meyer, Mylène / Frismand, Solène / Hingray, Coraline

International clinical psychopharmacology

2021 Volume 36, Issue 2, Page(s) 101–103

Abstract: Through this brief report, we described our clinical considerations about the treatment of motor fluctuations and psychiatric comorbidities in Huntington's disease, for example, aggressiveness and obsessive-compulsive disorders. Indeed, as classical ... ...

Abstract	Through this brief report, we described our clinical considerations about the treatment of motor fluctuations and psychiatric comorbidities in Huntington's disease, for example, aggressiveness and obsessive-compulsive disorders. Indeed, as classical treatment, for example, olanzapine and risperidone, were inefficient to improve motor disorders in our patient, we postulated that motor fluctuations could be influenced by the pharmacokinetic profile of oral risperidone. So, in line with recent practice in schizophrenia, we proposed empirically paliperidone 1-month long-acting injections hypothesized to improve motor fluctuations, treatment so far reserved to Huntington's disease patients who are noncompliant to oral risperidone. Improvement was soon observed concerning motor fluctuations, but also aggressiveness, supporting our initial hypothesis.
MeSH term(s)	Delayed-Action Preparations ; Humans ; Huntington Disease/drug therapy ; Paliperidone Palmitate/therapeutic use ; Treatment Outcome
Chemical Substances	Delayed-Action Preparations ; Paliperidone Palmitate (R8P8USM8FR)
Language	English
Publishing date	2021-01-21
Publishing country	England
Document type	Case Reports
ZDB-ID	632837-4
ISSN	1473-5857 ; 0268-1315
ISSN (online)	1473-5857
ISSN	0268-1315
DOI	10.1097/YIC.0000000000000346
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2162: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Real-world effectiveness studies of low doses of antipsychotics.

Berna, Fabrice / Schorr, Benoit / Javelot, Hervé / Dormegny-Jeanjean, Ludovic C / Foucher, Jack R

The lancet. Psychiatry

2022 Volume 9, Issue 7, Page(s) 536

MeSH term(s)	Antipsychotic Agents/therapeutic use ; Humans ; Schizophrenia/drug therapy
Chemical Substances	Antipsychotic Agents
Language	English
Publishing date	2022-06-09
Publishing country	England
Document type	Letter ; Comment
ISSN	2215-0374
ISSN (online)	2215-0374
DOI	10.1016/S2215-0366(22)00107-9
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Suicidality and psychotic episodes after starting aripiprazole: two case reports.

Meyer, Guillaume / Gitahy Falcao Faria, Clara / Beck, Marine / Riutort, Marielle / Michel, Bruno / Javelot, Hervé

International clinical psychopharmacology

2022 Volume 37, Issue 5, Page(s) 225–228

Abstract: Switching antipsychotic medication must be done carefully to ensure patient safety and a successful response. Here, we present two major psychotic decompensations that occurred following a switch to aripiprazole in two patients with schizophrenia. Mr. X ... ...

Abstract	Switching antipsychotic medication must be done carefully to ensure patient safety and a successful response. Here, we present two major psychotic decompensations that occurred following a switch to aripiprazole in two patients with schizophrenia. Mr. X was treated with paliperidone and experienced residual anxiety. Thus, a switch to aripiprazole was planned with risperidone and a gradual decrease in paliperidone. Initially, an increase in aripiprazole resulted in remission of his residual symptoms. However, two weeks later, he presented an anxiety relapse with persecutory ideas which required hospitalization. Mr. Y, who was treated for many years with risperidone, presented with a treatment resistant psychotic episode. A switch to aripiprazole enhanced his clinical condition. Despite the initial improvement, soon after discharge from the hospital, the patient presented psychotic symptoms requiring home intervention. Ultimately, the patient in the midst of a delusional recrudescence, had killed himself when the health care team arrived. A strong dopamine antagonist may lead to the development of dopaminergic upregulation. The addition of a partial agonist to these hypersensitive neurotransmitter pathways could explain these episodes. We agree with previous reports and recommend careful management when switching from strong dopamine antagonists to aripiprazole.
MeSH term(s)	Antipsychotic Agents/adverse effects ; Aripiprazole/adverse effects ; Humans ; Male ; Paliperidone Palmitate ; Risperidone/adverse effects ; Suicide
Chemical Substances	Antipsychotic Agents ; Aripiprazole (82VFR53I78) ; Risperidone (L6UH7ZF8HC) ; Paliperidone Palmitate (R8P8USM8FR)
Language	English
Publishing date	2022-06-02
Publishing country	England
Document type	Case Reports ; Journal Article
ZDB-ID	632837-4
ISSN	1473-5857 ; 0268-1315
ISSN (online)	1473-5857
ISSN	0268-1315
DOI	10.1097/YIC.0000000000000408
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2162: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: French Society for Biological Psychiatry and Neuropsychopharmacology (AFPBN) guidelines for the management of patients with partially responsive depression and treatment-resistant depression: Update 2024.

Yrondi, Antoine / Javelot, Hervé / Nobile, Bénédicte / Boudieu, Ludivine / Aouizerate, Bruno / Llorca, Pierre-Michel / Charpeaud, Thomas / Bennabi, Djamila / Lefrere, Antoine / Samalin, Ludovic

L'Encephale

2024

Abstract: Introduction: The purpose of this update is to add newly approved nomenclatures and treatments as well as treatments yet to be approved in major depressive disorder, thus expanding the discussions on the integration of resistance factors into the ... ...

Abstract	Introduction: The purpose of this update is to add newly approved nomenclatures and treatments as well as treatments yet to be approved in major depressive disorder, thus expanding the discussions on the integration of resistance factors into the clinical approach. Methods: Unlike the first consensus guidelines based on the RAND/UCLA Appropriateness Method, the French Association for Biological Psychiatry and Neuropsychopharmacology (AFPBN) developed an update of these guidelines for the management of partially responsive depression (PRD) and treatment-resistant depression (TRD). The expert guidelines combine scientific evidence and expert clinicians' opinions to produce recommendations for PRD and TRD. Results: The recommendations addressed three areas judged as essential for updating the previous 2019 AFPBN guidelines for the management of patients with TRD: (1) the identification of risk factors associated with TRD, (2) the therapeutic management of patients with PRD and TRD, and (3) the indications, the modalities of use and the monitoring of recent glutamate receptor modulating agents (esketamine and ketamine). Conclusion: These consensus-based guidelines make it possible to build bridges between the available empirical literature and clinical practice, with a highlight on the 'real world' of the clinical practice, supported by a pragmatic approach centred on the experience of specialised prescribers in TRD.
Language	English
Publishing date	2024-02-17
Publishing country	France
Document type	Journal Article
ZDB-ID	214431-1
ISSN	0013-7006
ISSN	0013-7006
DOI	10.1016/j.encep.2023.11.029
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ui II Zs.65: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: A case of paroxetine-induced antidepressant discontinuation syndrome related to pregnancy: time to redefine the syndrome?

Javelot, Hervé / Fichter, Aurore / Meyer, Guillaume / Michel, Bruno / Hingray, Coraline

Psychiatry research

2020 Volume 291, Page(s) 113259

Language	English
Publishing date	2020-06-26
Publishing country	Ireland
Document type	Letter
ZDB-ID	445361-x
ISSN	1872-7123 ; 1872-7506 ; 0925-4927 ; 0165-1781
ISSN (online)	1872-7123 ; 1872-7506
ISSN	0925-4927 ; 0165-1781
DOI	10.1016/j.psychres.2020.113259
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1541: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Quétiapine et hypersexualité : à propos de deux cas.

Meyer, Guillaume / Jumeau, Pauline / Fichter, Aurore / Kel, Charles-Louis / Michel, Bruno / Javelot, Hervé

Therapie

2021 Volume 77, Issue 3, Page(s) 381–384

Title translation	Quetiapine and hypersexuality: Two case reports.
MeSH term(s)	Antipsychotic Agents/adverse effects ; Bipolar Disorder/drug therapy ; Dibenzothiazepines/therapeutic use ; Humans ; Quetiapine Fumarate/therapeutic use
Chemical Substances	Antipsychotic Agents ; Dibenzothiazepines ; Quetiapine Fumarate (2S3PL1B6UJ)
Language	French
Publishing date	2021-04-21
Publishing country	France
Document type	Case Reports ; Letter
ZDB-ID	603474-3
ISSN	1958-5578 ; 0040-5957
ISSN (online)	1958-5578
ISSN	0040-5957
DOI	10.1016/j.therap.2021.04.007
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ue I Zs.272: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: High-dose quetiapine and therapeutic monitoring.

Javelot, Hervé / Rangoni, Francis / Weiner, Luisa / Michel, Bruno

European journal of hospital pharmacy : science and practice

2018 Volume 26, Issue 5, Page(s) 285–287

Abstract: Quetiapine is an atypical antipsychotic with a good safety profile permitting its administration beyond the maximum dose of 800 mg/day. We report the case of a patient with a resistant schizophrenia treated with high doses of quetiapine (up to 2000 mg/ ... ...

Abstract	Quetiapine is an atypical antipsychotic with a good safety profile permitting its administration beyond the maximum dose of 800 mg/day. We report the case of a patient with a resistant schizophrenia treated with high doses of quetiapine (up to 2000 mg/day) combined with drug monitoring and with favourable therapeutic response and tolerance.
Language	English
Publishing date	2018-08-06
Publishing country	England
Document type	Case Reports
ZDB-ID	2650179-X
ISSN	2047-9964 ; 2047-9956
ISSN (online)	2047-9964
ISSN	2047-9956
DOI	10.1136/ejhpharm-2018-001605
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito